eligibility_summary
Eligibility: Age 18–70, diagnosed refractory or relapsed multiple myeloma, expected survival >12 weeks, KPS >50%, ALT/AST <3×ULN, bilirubin <2.0 mg/dL, no serious heart/liver/kidney disease, relapse/nonremission after HSCT or transplant-ineligible, suitable for leukapheresis, consent. Exclude: pregnant/lactating, HIV/TB, active HBV/HCV, inadequate T-cell transfection/amplification, unstable vitals/uncooperative, severe psych, IL‑2 allergy, infection, autoimmune, physician judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Autologous anti-BCMA/FcRL5 CAR-T cells (gene-modified cellular therapy) given after lymphodepleting chemotherapy with fludarabine (purine analog) and cyclophosphamide (alkylating agent). Mechanisms: T cells are engineered with a chimeric antigen receptor that binds BCMA and FcRL5 on myeloma cells, CAR engagement triggers T-cell activation and cytotoxic killing, with dual targeting intended to limit antigen escape. Lymphodepletion reduces host lymphocytes to improve CAR-T expansion/persistence. Targets: BCMA and FcRL5 on malignant plasma cells/B-cell lineage in multiple myeloma, pathway: CAR-mediated T-cell signaling (CD3ζ/costimulatory domains) leading to selective elimination of BCMA+/FcRL5+ myeloma cells.